KR102636200B1 - Composition for cultivating cordyceps sinensis containing barley and cheonma as active ingredients and method for culturing cordyceps sinensis using the same - Google Patents
Composition for cultivating cordyceps sinensis containing barley and cheonma as active ingredients and method for culturing cordyceps sinensis using the same Download PDFInfo
- Publication number
- KR102636200B1 KR102636200B1 KR1020200178747A KR20200178747A KR102636200B1 KR 102636200 B1 KR102636200 B1 KR 102636200B1 KR 1020200178747 A KR1020200178747 A KR 1020200178747A KR 20200178747 A KR20200178747 A KR 20200178747A KR 102636200 B1 KR102636200 B1 KR 102636200B1
- Authority
- KR
- South Korea
- Prior art keywords
- cordyceps sinensis
- extract
- composition
- active ingredient
- present
- Prior art date
Links
- 241001248610 Ophiocordyceps sinensis Species 0.000 title claims abstract description 174
- 239000000203 mixture Substances 0.000 title claims abstract description 70
- 239000004480 active ingredient Substances 0.000 title claims abstract description 55
- 238000000034 method Methods 0.000 title claims description 21
- 238000012258 culturing Methods 0.000 title claims description 16
- 240000005979 Hordeum vulgare Species 0.000 title abstract description 25
- 235000007340 Hordeum vulgare Nutrition 0.000 title abstract description 25
- 239000000284 extract Substances 0.000 claims abstract description 89
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 33
- 208000020084 Bone disease Diseases 0.000 claims abstract description 26
- 230000003579 anti-obesity Effects 0.000 claims abstract description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 42
- 230000003405 preventing effect Effects 0.000 claims description 38
- 230000036541 health Effects 0.000 claims description 25
- 235000013376 functional food Nutrition 0.000 claims description 23
- 206010028980 Neoplasm Diseases 0.000 claims description 22
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 claims description 21
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 claims description 21
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 claims description 21
- 201000011510 cancer Diseases 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 15
- 229920002498 Beta-glucan Polymers 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 14
- 235000007164 Oryza sativa Nutrition 0.000 claims description 13
- 235000009566 rice Nutrition 0.000 claims description 13
- 230000036039 immunity Effects 0.000 claims description 10
- 238000012136 culture method Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 5
- 241000209094 Oryza Species 0.000 claims 6
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 30
- 230000006872 improvement Effects 0.000 abstract description 8
- 230000006806 disease prevention Effects 0.000 abstract description 3
- 240000006365 Vitis vinifera Species 0.000 abstract description 2
- 235000014787 Vitis vinifera Nutrition 0.000 abstract description 2
- 238000012364 cultivation method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 description 29
- 230000004069 differentiation Effects 0.000 description 27
- 206010061218 Inflammation Diseases 0.000 description 21
- 235000013305 food Nutrition 0.000 description 21
- 230000004054 inflammatory process Effects 0.000 description 21
- 238000004519 manufacturing process Methods 0.000 description 20
- 210000001789 adipocyte Anatomy 0.000 description 19
- 210000002997 osteoclast Anatomy 0.000 description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 15
- 230000001093 anti-cancer Effects 0.000 description 14
- 208000008589 Obesity Diseases 0.000 description 12
- 235000020824 obesity Nutrition 0.000 description 12
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 240000007594 Oryza sativa Species 0.000 description 7
- 210000000577 adipose tissue Anatomy 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- -1 bleaches Substances 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 210000000229 preadipocyte Anatomy 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 244000025254 Cannabis sativa Species 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 244000018633 Prunus armeniaca Species 0.000 description 4
- 235000009827 Prunus armeniaca Nutrition 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 230000010072 bone remodeling Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 3
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037180 bone health Effects 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 235000009120 camo Nutrition 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 235000005607 chanvre indien Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000011487 hemp Substances 0.000 description 3
- 239000012678 infectious agent Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 229920000310 Alpha glucan Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 206010065687 Bone loss Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 235000007516 Chrysanthemum Nutrition 0.000 description 2
- 240000005250 Chrysanthemum indicum Species 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 244000061456 Solanum tuberosum Species 0.000 description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 description 2
- 235000019764 Soybean Meal Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 201000010175 gallbladder cancer Diseases 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000004455 soybean meal Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000008728 vascular permeability Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241000254032 Acrididae Species 0.000 description 1
- 102000014777 Adipokines Human genes 0.000 description 1
- 108010078606 Adipokines Proteins 0.000 description 1
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010073360 Appendix cancer Diseases 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000003247 Caryota mitis Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 241000931705 Cicada Species 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 241001264174 Cordyceps militaris Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000305491 Gastrodia elata Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 241001656390 Ophiocordyceps sphecocephala Species 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 241000972672 Phellodendron Species 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 244000305267 Quercus macrolepis Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041969 Steatorrhoea Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000478 adipokine Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000005904 anticancer immunity Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 208000021780 appendiceal neoplasm Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000021405 artificial diet Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000016738 bone Paget disease Diseases 0.000 description 1
- 201000007327 bone benign neoplasm Diseases 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- 239000002121 nanofiber Substances 0.000 description 1
- 230000020395 negative regulation of osteoclast differentiation Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000001797 obstructive sleep apnea Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 206010036601 premature menopause Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004202 respiratory function Effects 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 206010039722 scoliosis Diseases 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 108010027322 single cell proteins Proteins 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 208000001162 steatorrhea Diseases 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
- A01G18/00—Cultivation of mushrooms
- A01G18/20—Culture media, e.g. compost
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
- A01G18/00—Cultivation of mushrooms
- A01G18/40—Cultivation of spawn
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01G—HORTICULTURE; CULTIVATION OF VEGETABLES, FLOWERS, RICE, FRUIT, VINES, HOPS OR SEAWEED; FORESTRY; WATERING
- A01G18/00—Cultivation of mushrooms
- A01G18/50—Inoculation of spawn
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Environmental Sciences (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
본 발명은 보리 및 천마를 유효성분으로 포함하는, 동충하초 배양용 조성물 및 동충하초 배양방법으로 배양된 동충하초 및 동충하초의 추출물로 항염, 항비만, 골질환 예방 및 개선 효과를 제공하는 것에 관한 것이다.The present invention relates to providing anti-inflammatory, anti-obesity, bone disease prevention and improvement effects with a composition for cultivating Cordyceps sinensis and extracts of Cordyceps sinensis and Cordyceps sinensis cultured using a Cordyceps sinensis cultivation method, which includes barley and raisin as active ingredients.
Description
본 발명은 보리 및 천마를 유효성분으로 포함하는 동충하초 배양용 조성물 및 이를 이용한 동충하초 배양방법에 관한 것으로, 구체적으로 동충하초를 보리 및 천마를 유효성분으로 포함하는 배지로 배양하였을 때 코디세핀 및 베타글루칸 기능성분이 증진되는 것을 확인하고, 또한 상기 동충하초 배양용 조성물로 배양한 동충하초를 이용 시 우수하게 뼈 건강을 증진하고, 항비만 및 항염 효과가 있어 약학조성물, 식품 조성물 및 사료 조성물을 제공하고자 하는 것이다.The present invention relates to a composition for cultivating Cordyceps sinensis containing barley and Chrysanthemum as active ingredients and a method for cultivating Cordyceps sinensis using the same. Specifically, when Cordyceps sinensis is cultured in a medium containing barley and Chrysanthemum as active ingredients, cordycepin and beta-glucan functionality are obtained. The purpose of this study was to provide pharmaceutical compositions, food compositions, and feed compositions by confirming that bone health is improved, and that using Cordyceps sinensis cultured with the Cordyceps sinensis culture composition excellently improves bone health and has anti-obesity and anti-inflammatory effects.
동충하초(Vegetable Worms)는 대부분 곤충에 기생하여 숙주가 되는 곤충의 시체에 자실체를 내는 것을 특징으로 하며 겨울에는 벌레이던 것이 여름에는 버섯으로 변한다는 뜻을 지닌다. 숙주의 종류에 따라 나비를 숙주로 하는 붉은동충하초(Cordyceps militaris), 매미를 숙주로 하는 매미동충하초(C. sobolifera), 벌을 숙주로 하는 벌동충하초(C. sphecocephala) 등이 있으며 그 밖에 딱정벌레, 메뚜기, 거미를 숙주로 하는 동충하초도 있다.Cordyceps (Vegetable Worms) is mostly parasitic on insects and is characterized by producing fruiting bodies on the corpses of insects that become hosts. This means that what is a worm in the winter turns into a mushroom in the summer. Depending on the type of host, there are Cordyceps militaris, whose host is a butterfly, C. sobolifera, whose host is a cicada, and C. sphecocephala, whose host is a bee. In addition, there are beetles and grasshoppers. , there is also Cordyceps sinensis that uses spiders as hosts.
면역 기능 강화, 항암, 호흡기 기능의 회복, 노화 억제, 피로 회복, 비만이나 빈혈 억제 등의 효과가 알려져 있다. It is known to have effects such as strengthening immune function, anticancer, recovering respiratory function, suppressing aging, relieving fatigue, and suppressing obesity and anemia.
상기 동충하초 버섯은 항암 효과 및 면역력 강화 효과가 있다고 공통적으로 보고되어 있으며 기능성 식품 및 건강보조식품 물론 의약품의 제조에도 널리 사용되고 있다. 동충하초를 의약품, 기능성 식품의 혼합 원료로서 사용하기 위해서는 자실체인 버섯을 채취하여 사용해야 하지만 버섯 자체가 자연 상태에서 번식이 잘 되지 않는다는 점과, 채취 남용으로 인해 자원 고갈 및 생태계 파괴가 야기된다는 문제점이 있다.The Cordyceps sinensis mushroom is commonly reported to have anti-cancer effects and immunity-boosting effects, and is widely used in the manufacture of functional foods and health supplements as well as pharmaceuticals. In order to use Cordyceps sinensis as a mixed raw material for medicines and functional foods, mushrooms, which are fruiting bodies, must be collected and used. However, there is a problem in that mushrooms themselves do not reproduce well in nature, and overuse of collection causes resource depletion and destruction of the ecosystem. .
또한, 톱밥 등을 이용하여 자실체를 재배하는 방법이 이용되기도 하나 이러한 방법도 재배 기간만 수개월이 소요된다. 산업적으로 사용할 수 있을 정도로 원료를 공급하기 위해서도 대량의 생산 시설 및 경비가 소요된다는 난점 때문에 대량 생산의 수요를 충족시키지 못하고 있다.In addition, a method of cultivating fruiting bodies using sawdust, etc. is also used, but this method also requires several months of cultivation. It is not possible to meet the demand for mass production due to the difficulty of requiring large production facilities and costs to supply raw materials sufficient for industrial use.
이와 같이, 동충하초는 항암제, 면역 증강제로서 효과가 있음에도 그 공급이 제한적이며 대량 생산 및 속성 생산이 용이하지 않아 널리 활용되지 못하고 있다.Likewise, although Cordyceps sinensis is effective as an anticancer agent and an immune enhancer, its supply is limited and mass production and rapid production are not easy, so it is not widely used.
따라서, 버섯균의 자실체와 동등한 효과를 나타내는 균사체를 생산할 수 있는 대량 배양 방법에 대한 연구가 최근 활발하게 이루어지고 있다.Therefore, research on mass culture methods that can produce mycelium that has the same effect as the fruiting body of mushroom fungi has been actively conducted recently.
이러한 배경하에, 본 발명자들은 항염, 항비만, 및 뼈건강 증진 효과 등의 약리효과를 더하기 위해 동충하초 균사체를 보리 및 천마를 포함한 배지에 배양하는 방법의 도입에 대해 예의 노력하여 연구한 결과, 보리 및 천마만을 유효성분으로 포함하는 조성물에서 다른 구성성분을 추가하지 않았을 때에도 효과적으로 동충하초를 배양할 수 있음을 확인함으로써, 본 발명을 완성하였다.Against this background, the present inventors have made diligent efforts to study the introduction of a method of culturing Cordyceps sinensis mycelium in a medium containing barley and raisin in order to add pharmacological effects such as anti-inflammatory, anti-obesity, and bone health promotion effects, and as a result, barley and The present invention was completed by confirming that Cordyceps sinensis can be effectively cultured in a composition containing only Cheonma as an active ingredient even when no other components are added.
본 발명의 하나의 목적은 보리 및 천마를 유효성분으로 포함하는, 동충하초 배양용 조성물을 제공하는 것이다.One object of the present invention is to provide a composition for cultivating Cordyceps sinensis, which includes barley and hemp as active ingredients.
본 발명의 다른 하나의 목적은 동충하초 균주를 보리 및 천마를 유효성분으로 포함한 배지로 배양하여 동충하초 자실체를 생성하는 제1단계 및 상기 동충하초 자실체를 생육재배하는 제2단계를 포함하는 동충하초 배양방법을 제공하는 것이다.Another object of the present invention is to provide a Cordyceps sinensis culturing method comprising a first step of producing Cordyceps sinensis fruiting bodies by cultivating a Cordyceps sinensis strain in a medium containing barley and apricots as active ingredients, and a second step of growing and cultivating the Cordyceps sinensis fruiting bodies. It is done.
본 발명의 또 다른 하나의 목적은 동충하초 균주를 보리 및 천마를 유효성분으로 포함한 배지로 배양하여 동충하초 자실체를 생성하는 제1단계 및 상기 동충하초 자실체를 생육재배하는 제2단계를 포함하는 동충하초의 기능성 성분 증진방법을 제공하는 것이다.Another object of the present invention is to provide functional ingredients of Cordyceps sinensis, including a first step of producing a Cordyceps sinensis fruiting body by cultivating a Cordyceps sinensis strain in a medium containing barley and Hemp as active ingredients, and a second step of growing and cultivating the Cordyceps sinensis fruiting body. It provides ways to improve.
본 발명의 또 다른 하나의 목적은 본 발명의 배양방법으로 배양된 동충하초를 제공하는 것이다.Another object of the present invention is to provide Cordyceps sinensis cultured by the culture method of the present invention.
본 발명의 또 다른 하나의 목적은 상기 동충하초의 추출물을 유효성분으로 포함하는 면역력 개선용 건강기능식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a health functional food composition for improving immunity containing the extract of Cordyceps sinensis as an active ingredient.
본 발명의 또 다른 하나의 목적은 상기 동충하초의 추출물을 유효성분으로 포함하는 항염용 건강기능식품 조성물을 제공하는 것이다.Another object of the present invention is to provide an anti-inflammatory health functional food composition containing the extract of Cordyceps sinensis as an active ingredient.
본 발명의 또 다른 하나의 목적은 상기 동충하초의 추출물을 유효성분으로 포함하는 암 예방 또는 개선용 건강기능식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a health functional food composition for preventing or improving cancer containing the extract of Cordyceps sinensis as an active ingredient.
본 발명의 또 다른 하나의 목적은 상기 동충하초의 추출물을 유효성분으로 포함하는 항비만용 건강기능식품 조성물을 제공하는 것이다.Another object of the present invention is to provide an anti-obesity health functional food composition containing the extract of Cordyceps sinensis as an active ingredient.
본 발명의 또 다른 하나의 목적은 상기 동충하초의 추출물을 유효성분으로 포함하는 골질환 예방 또는 개선용 건강기능식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a health functional food composition for preventing or improving bone disease containing the extract of Cordyceps sinensis as an active ingredient.
본 발명의 또 다른 하나의 목적은 상기 동충하초의 추출물을 유효성분으로 포함하는 항염용 약학 조성물을 제공하는 것이다.Another object of the present invention is to provide an anti-inflammatory pharmaceutical composition containing the extract of Cordyceps sinensis as an active ingredient.
본 발명의 또 다른 하나의 목적은 상기 동충하초의 추출물을 유효성분으로 포함하는 항염용 사료 조성물을 제공하는 것이다.Another object of the present invention is to provide an anti-inflammatory feed composition containing the extract of Cordyceps sinensis as an active ingredient.
본 발명의 또 다른 하나의 목적은 상기 동충하초의 추출물을 유효성분으로 포함하는 암 예방 또는 개선용 약학 조성물을 제공하는 것이다.Another object of the present invention is to provide a pharmaceutical composition for preventing or improving cancer containing the extract of Cordyceps sinensis as an active ingredient.
본 발명의 또 다른 하나의 목적은 상기 동충하초의 추출물을 유효성분으로 포함하는 암 예방 또는 개선용 사료 조성물을 제공하는 것이다.Another object of the present invention is to provide a feed composition for preventing or improving cancer containing the extract of Cordyceps sinensis as an active ingredient.
본 발명의 또 다른 하나의 목적은 상기 동충하초의 추출물을 유효성분으로 포함하는 항비만용 약학 조성물을 제공하는 것이다.Another object of the present invention is to provide an anti-obesity pharmaceutical composition containing the extract of Cordyceps sinensis as an active ingredient.
본 발명의 또 다른 하나의 목적은 상기 동충하초의 추출물을 유효성분으로 포함하는 항비만용 사료 조성물을 제공하는 것이다.Another object of the present invention is to provide an anti-obesity feed composition containing the extract of Cordyceps sinensis as an active ingredient.
본 발명의 또 다른 하나의 목적은 상기 동충하초의 추출물을 유효성분으로 포함하는 골질환 예방 또는 개선용 약학 조성물을 제공하는 것이다.Another object of the present invention is to provide a pharmaceutical composition for preventing or improving bone disease containing the extract of Cordyceps sinensis as an active ingredient.
본 발명의 또 다른 하나의 목적은 상기 동충하초의 추출물을 유효성분으로 포함하는 골질환 예방 또는 개선용 사료 조성물을 제공하는 것이다.Another object of the present invention is to provide a feed composition for preventing or improving bone disease containing the extract of Cordyceps sinensis as an active ingredient.
본 발명의 또 다른 하나의 목적은 상기 동추하초의 추출물은 메탄올(MeOH), 물 및 프레타놀(prethano)로 이루어진 군에서 선택된 하나 이상의 추출용매로 추출된 것인, 동충하초 추출물을 제공하는 것이다.Another object of the present invention is to provide an extract of Cordyceps sinensis, wherein the extract of Cordyceps sinensis is extracted with one or more extraction solvents selected from the group consisting of methanol (MeOH), water, and prethano.
이를 구체적으로 설명하면 다음과 같다. 한편, 본 발명에서 개시된 각각의 설명 및 실시형태는 각각의 다른 설명 및 실시 형태에도 적용될 수 있다. 즉, 본 발명에서 개시된 다양한 요소들의 모든 조합이 본 발명의 범주에 속한다. 또한, 하기 기술된 구체적인 서술에 의하여 본 발명의 범주가 제한된다고 볼 수 없다.This is explained in detail as follows. Meanwhile, each description and embodiment disclosed in the present invention may also be applied to each other description and embodiment. That is, all combinations of the various elements disclosed in the present invention fall within the scope of the present invention. Additionally, the scope of the present invention cannot be considered limited by the specific description described below.
이하, 본 발명을 보다 자세히 설명한다.Hereinafter, the present invention will be described in more detail.
전술한 목적을 달성하기 위한 본 발명의 제1양태는, 보리 및 천마를 유효성분으로 포함하는, 동충하초 배양용 조성물을 제공한다.The first aspect of the present invention for achieving the above-described object provides a composition for culturing Cordyceps sinensis, which includes barley and apricot as active ingredients.
본 발명의 용어, "보리"는 식이섬유를 다량으로 함유한 벼과에 속하는 작물로 자양강장 및 혈당조절에 도움을 주는 작물을 의미한다. 구체적으로, 새쌀, 새찰쌀, 누리찰, 또는 베타원 품종을 포함하는 것일 수 있다. 더욱 구체적으로, 베타원 품종일 수 있다.The term "barley" in the present invention refers to a crop belonging to the Poaceae family that contains a large amount of dietary fiber and helps in nourishment and blood sugar control. Specifically, it may include new rice, new glutinous rice, Nurichal, or Beta One varieties. More specifically, it may be a beta one variety.
상기 보리는 동충하초 배양용 조성물 대비 60 중량% 내지 80 중량%로 포함하는 것일 수 있으나, 이에 제한되는 것은 아니다.The barley may be included in an amount of 60% to 80% by weight compared to the composition for cultivating Cordyceps sinensis, but is not limited thereto.
본 발명의 용어, "천마"는 여러살이 기생식물이며 참나무 종류의 썩은 그루터기에 나는 버섯의 균사에 붙어사는 것을 의미한다. 구체적으로, 학명은 Gastrodia elata BLUME0이며, 진정, 진경의 효능이 있고, 적용질환은 두통이나 현기증을 비롯해 팔다리의 근육이 굳어지고 감각이 없어지는 증세, 반신불수, 언어장애, 고혈압, 어린아이의 간질병, 유행성 뇌수막염 등의 질환에 약효가 있는 것으로 알려져 있다.The term "cheonma" of the present invention refers to a multi-year-old parasitic plant that lives attached to the mycelia of mushrooms that grow on rotten stumps of oak trees. Specifically, the scientific name is Gastrodia elata BLUME0, and it has sedative and antispasmodic effects, and the diseases it is applied to include headaches and dizziness, stiffening and loss of sensation in the muscles of the limbs, hemiplegia, speech impediment, high blood pressure, and epilepsy in children. It is known to be effective in treating diseases such as epidemic meningitis.
상기 천마는 동충하초 배양용 조성물 대비 20 중량% 내지 40 중량%로 포함하는 것일 수 있으나 이에 제한되는 것은 아니다.The celestial root may be included in an amount of 20% to 40% by weight compared to the composition for cultivating Cordyceps sinensis, but is not limited thereto.
본 발명의 용어, "동충하초"는 곤충기생형 약용버섯으로 겨울에는 곤충 몸에 있다가 여름에는 풀처럼 나타나는 데서 이름이 지어졌고, 항암, 면역, 노화 방지에 효과가 있는 버섯을 의미한다. 구체적으로, 상기 동충하초 균주는 순수하게 분리하여 배양한 유전적으로 동질의 핵을 갖는 미생물을 의미하는 것으로서, 도동, 도원 또는 강원 종균일 수 있다. 더욱 구체적으로, 강원 종균일 수 있다.The term of the present invention, "Cordyceps sinensis", is an insect-parasitic medicinal mushroom, so named because it resides in the body of insects in the winter and appears like grass in the summer, and refers to mushrooms that are effective in anti-cancer, immunity, and anti-aging. Specifically, the Cordyceps sinensis strain refers to a microorganism with a genetically identical nucleus that has been purely isolated and cultured, and may be a Dodong, Dowon, or Gangwon seed strain. More specifically, it may be Gangwon seed.
본 발명의 용어, "배양"은 미생물 식물 동물의 알, 동식물의 조직 일부를 인공적으로 발육, 증식 시키는 조작 또는 배지, 수단, 온도, pH, 습도, 산소 유무 따위를 조절하는 것을 의미한다.The term "culture" of the present invention refers to the manipulation of artificially developing and multiplying the eggs of microorganisms, plants and animals, and parts of tissues of animals and plants, or by controlling the medium, means, temperature, pH, humidity, presence or absence of oxygen, etc.
구체적으로, 본 발명의 배양용 조성물은 동충하초가 배양되는 배지일 수 있으며, 구체적으로는 코디세핀 및 베타글루칸의 함량을 증진시키는 것일 수 있다.Specifically, the culture composition of the present invention may be a medium in which Cordyceps sinensis is cultured, and may specifically enhance the content of cordycepin and beta-glucan.
상기 배양 조성물로 배양된 동충하초는 코디세핀 및 베타글루칸의 함량이 향상되고, 이러한 동충하초는, NO생성 억제, 사이토카인 활성 억제, 지방세포 분화 억제 및 파골세포 분화억제 효과를 제공할 수 있다.Cordyceps sinensis cultured with the above culture composition has an improved content of cordycepin and beta-glucan, and this Cordyceps sinensis can provide the effects of suppressing NO production, suppressing cytokine activity, suppressing adipocyte differentiation, and suppressing osteoclast differentiation.
본 발명의 용어, "코디세핀(codycepin)"은 아데노신과 구조가 유사하며 단백질 합성의 조기 종결을 일으킬 수 있는 천연약물로, 항암, 노화방지, 항균, 항 바이러스, 면역력 증진, 신진대사 개선, 활성산소 제거 등 각종 약리작용이 있는 것을 의미한다. 구체적으로, 일반적으로 동충하초에서 추출될 수 있고, 야생 동충하초에 함유된 코디세핀 함량은 지극히 미량이고 함량이 안정적이지 않아 추출또한 어려우므로, 코디세핀 함량을 높이는 인공 재배기술이 필요하다.The term "codycepin" of the present invention is a natural drug that has a similar structure to adenosine and can cause early termination of protein synthesis. It is anti-cancer, anti-aging, antibacterial, antiviral, enhances immunity, improves metabolism, and has anti-inflammatory properties. This means that it has various pharmacological effects, such as oxygen removal. Specifically, it can generally be extracted from Cordyceps sinensis, and the cordycepin content contained in wild Cordyceps sinensis is extremely small and the content is not stable, making extraction difficult, so artificial cultivation technology to increase the cordycepin content is needed.
본 발명의 용어, "베타글루칸(β-glucan)"는 다당류의 일종으로 면역증강작용을 가지고 있으며 효모의 세포벽, 버섯류, 곡류 등에 존재하는 것을 의미한다. 구체적으로, 인간 정상 세포의 면역기능을 활성화시켜 암세포의 증식과 재발을 억제하고 혈당과 혈중 콜레스테롤을 감소시키며 지질대사를 개선하여 체지방 형성과 축적을 억제하는 것일 수 있다.The term "β-glucan" in the present invention refers to a type of polysaccharide that has an immune-enhancing effect and is present in the cell walls of yeast, mushrooms, grains, etc. Specifically, it may suppress the proliferation and recurrence of cancer cells by activating the immune function of human normal cells, reduce blood sugar and blood cholesterol, and improve lipid metabolism to suppress body fat formation and accumulation.
본 발명의 용어 "NO생성 억제"는 염증상태에서 나타나는 NO가 생성으로 혈관 투과성, 부종 등 염증 반응을 촉진시키는 것을 억제하는 것을 의미한다. 구체적으로, NO는 혈관 투과성, 부종 등의 염증 반응을 촉진시킬 뿐만 아니라 염증 매개체의 생합성을 촉진하고 혈관을 확장시키거나 암 조직의 성장을 억제하고, 바이러스나 세균들의 증식을 저해하거나 직접 사멸시키는 등 인체 면역 염증 반응에 있어서 중요한 역할을 한다. 따라서, 항염증 활성을 가지는 물질에 대해서 NO생성 억제에 대한 검토는 필수적으로 수행되고, NO생성 억제율로 항염효과를 확인할 수 있다.The term "inhibition of NO production" in the present invention refers to suppressing the promotion of inflammatory reactions such as vascular permeability and edema due to the production of NO that occurs in inflammatory conditions. Specifically, NO not only promotes inflammatory reactions such as vascular permeability and edema, but also promotes the biosynthesis of inflammatory mediators, dilates blood vessels, inhibits the growth of cancer tissue, inhibits the proliferation of viruses and bacteria, or directly kills them. It plays an important role in the human immune inflammatory response. Therefore, it is essential to examine the inhibition of NO production for substances with anti-inflammatory activity, and the anti-inflammatory effect can be confirmed by the NO production inhibition rate.
본 발명의 용어 "사이토카인(cytokine)"은 면역 세포가 분비하는 단백질을 통틀어 일컫는 말이다. 사이토카인은 세포로부터 분비된 후 다른 세포나 분비한 세포 자신에게 영향을 줄 수 있다. 즉, 대식세포의 증식을 유도하거나 분비 세포 자신의 분화를 촉진하기도 한다. 사이토카인은 수용체를 통해서 작용하며, 면역계에서 특히 중요하다. 사이토카인은 건강 유지와 질병에도 중요한데, 특히 감염, 면역반응, 염증, 외상, 폐혈증, 암 및 생식 등에 대한 신체의 반응에 중요하다. The term “cytokine” in the present invention refers collectively to proteins secreted by immune cells. After cytokines are secreted from a cell, they can affect other cells or the secreting cell itself. In other words, it induces the proliferation of macrophages or promotes the differentiation of secretory cells themselves. Cytokines act through receptors and are particularly important in the immune system. Cytokines are important for maintaining health and disease, especially in the body's response to infection, immune response, inflammation, trauma, sepsis, cancer, and reproduction.
병원균, 바이러스들이 숙주 안에 들어오면, 병원균을 인식하고 신호를 보내 전사인자인 NF-kB을 활성시키고 이는 염증 유전자 물질(사이토카인)을 유도하여 여러 질병을 유발한다. 본 발명의 동충하초는 NO생성 억제 및 사이토카인 활성을 억제하여 항염효과를 나타내는 것을 확인하였다.When pathogens and viruses enter the host, they recognize the pathogen and send a signal to activate the transcription factor NF-kB, which induces inflammatory gene substances (cytokines) and causes various diseases. It was confirmed that Cordyceps sinensis of the present invention exhibits an anti-inflammatory effect by suppressing NO production and cytokine activity.
또한, 상기 배양용 조성물에 추가로 첨가물이 추가될 수 있으며, 첨가물은 예를 들어, 기타 성장 촉진 화합물, 성장인자, 또는 아미노산을 포함할 수 있다.Additionally, additives may be added to the culture composition, and the additives may include, for example, other growth promoting compounds, growth factors, or amino acids.
또한, 본 발명의 제2양태는 동충하초 균주를 보리 및 천마를 유효성분으로 포함한 배지로 배양하여 동충하초 자실체를 생성하는 제1단계 및 상기 동충하초 자실체를 생육재배하는 제2단계를 포함하는 동충하초 배양방법을 제공한다.In addition, the second aspect of the present invention is a Cordyceps sinensis culturing method comprising a first step of producing Cordyceps sinensis fruiting bodies by culturing the Cordyceps sinensis strain in a medium containing barley and apricots as active ingredients, and a second step of growing and cultivating the Cordyceps sinensis fruiting bodies. to provide.
본 발명의 용어 "자실체"는 균류의 포자를 만드는 기관을 의미한다. 구체적으로, 곰팡이가 포자형성을 위해 만든 복잡한 구조체이고, 대형의 자실체는 버섯이라고 한다.The term "fruiting body" in the present invention refers to the organ that produces spores of a fungus. Specifically, it is a complex structure created by fungi for spore formation, and the large fruiting body is called a mushroom.
본 발명의 용어, "재배"는 발달하여 크게 자라나도록 일정 목적을 가지고 경지에 작물을 길러 수확을 올리는 것을 의미한다.The term "cultivation" in the present invention means growing crops on farmland for the purpose of growing crops and increasing harvest.
또한, 본 발명의 제3양태는 동충하초 균주를 보리 및 천마를 유효성분으로 포함한 배지로 배양하여 동충하초 자실체를 생성하는 제1단계 및 상기 동충하초 자실체를 생육재배하는 제2단계를 포함하는 동충하초의 기능성 성분 증진방법을 제공한다.In addition, the third aspect of the present invention is a functional component of Cordyceps sinensis comprising a first step of producing a Cordyceps sinensis fruiting body by culturing a Cordyceps sinensis strain in a medium containing barley and apricots as active ingredients, and a second step of growing and cultivating the Cordyceps sinensis fruiting body. Provides improvement methods.
상기 동충하초의 기능성 성분은 베타글루칸, 코디세핀, 코디세픽산(Codycepic acid, Mannitol), 코디세픽 폴리사카라이드(Codycepic Polysaccharide), SOD(superoxide dismutase), 아미노산, 비타민 전구체 등이 알려져 있으며, 구체적으로, 본 발명의 기능성 성분 증진방법으로 코디세핀 및 베타글루칸 함량을 증진 시킬 수 있으나, 이에 제한되지 않는다.The functional ingredients of Cordyceps sinensis are known to include beta-glucan, cordycepin, cordycepic acid (mannitol), cordycepic polysaccharide, SOD (superoxide dismutase), amino acids, vitamin precursors, etc. Specifically, Cordycepin and beta-glucan content can be increased using the functional ingredient enhancement method of the present invention, but is not limited thereto.
또한, 본 발명의 제4양태는 본 발명의 배양방법으로 배양된 동충하초를 제공한다.Additionally, a fourth aspect of the present invention provides Cordyceps sinensis cultured by the culture method of the present invention.
또한, 본 발명의 제5양태는 상기 동충하초의 추출물을 유효성분으로 포함하는 면역력 개선용 건강기능식품 조성물을 제공한다.In addition, the fifth aspect of the present invention provides a health functional food composition for improving immunity containing the extract of Cordyceps sinensis as an active ingredient.
또한, 본 발명의 제6양태는 상기 동충하초의 추출물을 유효성분으로 포함하는 항염용 건강기능식품 조성물을 제공한다.In addition, the sixth aspect of the present invention provides an anti-inflammatory health functional food composition containing the extract of Cordyceps sinensis as an active ingredient.
또한, 본 발명의 제7양태는 상기 동충하초의 추출물을 유효성분으로 포함하는 암 예방 또는 개선용 건강기능식품 조성물을 제공한다.In addition, the seventh aspect of the present invention provides a health functional food composition for preventing or improving cancer containing the extract of Cordyceps sinensis as an active ingredient.
또한, 본 발명의 제8양태는 상기 동충하초의 추출물을 유효성분으로 포함하는 항비만용 건강기능식품 조성물을 제공한다.In addition, the eighth aspect of the present invention provides an anti-obesity health functional food composition containing the extract of Cordyceps sinensis as an active ingredient.
또한, 본 발명의 제9양태는 상기 동충하초의 추출물을 유효성분으로 포함하는 골질환 예방 또는 개선용 건강기능식품 조성물을 제공한다.In addition, the ninth aspect of the present invention provides a health functional food composition for preventing or improving bone disease containing the extract of Cordyceps sinensis as an active ingredient.
또한, 본 발명의 제10양태는 상기 동충하초의 추출물을 유효성분으로 포함하는 항염용 약학 조성물을 제공한다.In addition, the tenth aspect of the present invention provides an anti-inflammatory pharmaceutical composition containing the extract of Cordyceps sinensis as an active ingredient.
또한, 본 발명의 제11양태는 상기 동충하초의 추출물을 유효성분으로 포함하는 항염용 사료 조성물을 제공한다.In addition, the 11th aspect of the present invention provides an anti-inflammatory feed composition containing the extract of Cordyceps sinensis as an active ingredient.
또한, 본 발명의 제12양태는 상기 동충하초의 추출물을 유효성분으로 포함하는 암 예방 또는 개선용 약학 조성물을 제공한다.In addition, the twelfth aspect of the present invention provides a pharmaceutical composition for preventing or improving cancer comprising the extract of Cordyceps sinensis as an active ingredient.
또한, 본 발명의 제13양태는 상기 동충하초의 추출물을 유효성분으로 포함하는 암 예방 또는 개선용 사료 조성물을 제공한다.In addition, the 13th aspect of the present invention provides a feed composition for preventing or improving cancer comprising the extract of Cordyceps sinensis as an active ingredient.
또한, 본 발명의 제14양태는 상기 동충하초의 추출물을 유효성분으로 포함하는 항비만용 약학 조성물을 제공한다.In addition, the fourteenth aspect of the present invention provides an anti-obesity pharmaceutical composition containing the extract of Cordyceps sinensis as an active ingredient.
또한, 본 발명의 제15양태는 상기 동충하초의 추출물을 유효성분으로 포함하는 항비만용 사료 조성물을 제공한다.In addition, the fifteenth aspect of the present invention provides an anti-obesity feed composition containing the extract of Cordyceps sinensis as an active ingredient.
또한, 본 발명의 제16양태는 상기 동충하초의 추출물을 유효성분으로 포함하는 골질환 예방 또는 개선용 약학 조성물을 제공한다.In addition, the sixteenth aspect of the present invention provides a pharmaceutical composition for preventing or improving bone disease comprising the extract of Cordyceps sinensis as an active ingredient.
또한, 본 발명의 제17양태는 상기 동충하초의 추출물을 유효성분으로 포함하는 골질환 예방 또는 개선용 사료 조성물을 제공한다.In addition, the 17th aspect of the present invention provides a feed composition for preventing or improving bone disease comprising the extract of Cordyceps sinensis as an active ingredient.
본 발명의 용어, "항염"은 염증 발생을 억제 또는 방지하는 것을 의미하는 것으로서, 특별히 제한되지는 않으나, 세포의 손상이나 외부 감염원에 의해 발생하는 것일 수 있다.The term "anti-inflammatory" of the present invention refers to suppressing or preventing inflammation, and is not particularly limited, but may be caused by cell damage or external infectious agents.
상기 "염증"은 조직(세포)의 손상이나 외부 감염원(박테리아, 바이러스, 곰팡이, 다양한 종류의 알레르기 유발물질)에 감염되었을 때 국소 혈관과 체액중 각종 염증 매개인자 및 면역세포가 관련되어 효소 활성화 염증 매개물질 분비, 체액 침윤, 세포 이동, 조직 파괴 등 일련의 복합적인 생리적 반응과 홍반, 부종, 발열, 통증 등 외적 증상을 나타낸다. 정상인 경우 염증 반응은 외부감염원을 제거하고 손상된 조직을 재생하여 생명체 기능 회복을 하지만 항원이 제거되지 않거나 내부 물질이 원인이 되어 염증 반응이 과도하거나 지속적으로 일어나면 오히려 점막손상을 촉진하고, 그 결과 일부에서는 암 발생 등의 질환에 이른다.The "inflammation" is an enzyme-activated inflammation caused by various inflammatory mediators and immune cells in local blood vessels and body fluids when tissue (cells) are damaged or infected with external infectious agents (bacteria, viruses, molds, various types of allergens). It shows a series of complex physiological reactions such as mediator secretion, body fluid infiltration, cell migration, and tissue destruction, as well as external symptoms such as erythema, edema, fever, and pain. In normal cases, the inflammatory response removes external infectious agents and regenerates damaged tissues to restore the function of the organism, but if the inflammatory response occurs excessively or continuously due to antigens not being removed or internal substances as the cause, it actually promotes mucosal damage, and as a result, in some cases, It can lead to diseases such as cancer.
본 발명에서 용어, "염증 관련 질환"은 염증을 주병변으로 하는 질병을 의미한다. 염증은 선천 면역에 의해 매개되는 비특이적 반응으로, 병원체에 의해 일어나는 경우 병원체의 종류나 이전 감염 여부에 관계없이 일어난다. 선천 면역뿐만 아니라 일부 국소적 적응면역 역시 염증에 관여한다. 염증은 감염을 치유하거나 조직의 재생을 증진시키는 보호 기능을 가지지만, 동시에 염증의 결과로 조직의 손상이나 질병이 일어날 수 있다. 프롤로테라피 등과 같이 의도적으로 염증 반응을 유도하여 조직의 재생을 꾀하는 방법도 있다. 구체적으로, 베체트병, 크론병, 류마티스관절염, 모소낭, 지루성 피부염, 건선, 루퍼스, 만성폐색성폐질환, 과민성장질환, 소화지방변증, 혈관염 등을 포함할 수 있다.In the present invention, the term “inflammation-related disease” refers to a disease whose main lesion is inflammation. Inflammation is a non-specific response mediated by innate immunity, and when caused by a pathogen, it occurs regardless of the type of pathogen or previous infection. Not only innate immunity but also some local adaptive immunity are involved in inflammation. Inflammation has a protective function to heal infection or promote tissue regeneration, but at the same time, tissue damage or disease can occur as a result of inflammation. There are also methods, such as prolotherapy, that seek to regenerate tissue by intentionally inducing an inflammatory response. Specifically, it may include Behcet's disease, Crohn's disease, rheumatoid arthritis, hair follicles, seborrheic dermatitis, psoriasis, lupus, chronic obstructive pulmonary disease, irritable bowel disease, digestive steatorrhea, vasculitis, etc.
본 발명의 용어, "항암"은 암세포의 증식을 막는 것으로 암에 저항하는 효력을 의미한다. 구체적으로, 상기 암은 갑상선암, 위암, 대장암, 폐암, 유방암, 간암, 전립선암, 췌장암, 담낭암, 담도암, 비호지킨 림프종, 혈액암, 피부암, 뼈암, 심장암, 부신피질암, 항문암, 충수암, 담낭암, 방광암, 고환암, 난소암, 식도암, 뇌암, 코인두암 등을 포함할 수 있다.As used herein, the term “anti-cancer” refers to the effect of preventing cancer by preventing the proliferation of cancer cells. Specifically, the cancers include thyroid cancer, stomach cancer, colon cancer, lung cancer, breast cancer, liver cancer, prostate cancer, pancreatic cancer, gallbladder cancer, biliary tract cancer, non-Hodgkin's lymphoma, blood cancer, skin cancer, bone cancer, heart cancer, adrenocortical cancer, anal cancer, This may include appendix cancer, gallbladder cancer, bladder cancer, testicular cancer, ovarian cancer, esophagus cancer, brain cancer, and nasopharyngeal cancer.
본 발명의 용어, "체지방 감소"는 체중의 변화가 없음에도 불구하고, 체지방을 감소시켜 체지방율이 감소되는 효과, 및 체지방의 증가를 억제하여 체지방율의 증가를 억제하는 효과를 의미한다.The term "body fat reduction" in the present invention refers to the effect of reducing body fat and thus the body fat percentage, and the effect of suppressing the increase in body fat percentage by suppressing the increase in body fat, despite no change in body weight.
본 발명의 용어, "비만"은 체내에 필요한 에너지보다 과다 섭취하거나 섭취된 에너지보다 적게 소비함에 따라 발생하는 체내의 에너지 불균형 상태로 지방조직이 과다한 상태를 의미한다. 구체적으로, 비만은 체내의 지방전구세포가 지방축적으로 인해 지방세포로 분화되는 양이 급증하는 것이 주된 원인이고, 비만 관련 질환을 일으킬 수 있다.As used herein, the term “obesity” refers to a state of excessive adipose tissue in the body due to energy imbalance caused by consuming too much energy or consuming less energy than the body needs. Specifically, obesity is mainly caused by a rapid increase in the amount of preadipocytes in the body differentiating into adipocytes due to fat accumulation, which can cause obesity-related diseases.
본 발명의 용어, "비만 관련 질환"은 비만으로 인해 지방세포가 과다하게 축적되어 여러 가지 이상을 초래하여 발생하는 질환을 의미한다. 지방세포에서 분비되는 아디포카인이라는 물질들이 체내 대사를 조절하게 되는데, 비만으로 인해 이러한 물질들의 불균형을 초래하게 되어 지방과 포도당 대사에 이상을 초래한다. 구체적으로, 비만 관련 질환은 고혈압, 당뇨병, 고지혈증, 지방간, 담석증, 폐쇄성 수면 무호흡증, 생리불순, 다낭성 난소 질환, 불임증, 성욕감퇴, 우울증, 퇴행성 관절염, 통풍, 대장암, 췌장암, 전립선암, 유방암 등 각종암을 포함할 수 있다.As used herein, the term “obesity-related disease” refers to a disease caused by excessive accumulation of fat cells due to obesity, resulting in various abnormalities. Substances called adipokines secreted from fat cells regulate metabolism in the body, but obesity causes an imbalance in these substances, causing abnormalities in fat and glucose metabolism. Specifically, obesity-related diseases include high blood pressure, diabetes, hyperlipidemia, fatty liver, gallstones, obstructive sleep apnea, menstrual irregularities, polycystic ovarian disease, infertility, decreased libido, depression, degenerative arthritis, gout, colon cancer, pancreatic cancer, prostate cancer, breast cancer, etc. May include various cancers.
본 발명의 용어, "골질환"은 특별히 제한되지 않으나, 구체적으로는 골다공증, 골연화증, 구루병, 파제트병, 측만증, 골수염, 양성 골종양, 또는 파제트병일 수 있다.The term "bone disease" in the present invention is not particularly limited, but may specifically include osteoporosis, osteomalacia, rickets, Paget's disease, scoliosis, osteomyelitis, benign bone tumor, or Paget's disease.
상기 "골다공증"은 뼈의 강도가 약해져서 쉽게 골절되는 골격계 질환이다. 구체적으로, 유전적인 요인, 조기 폐경, 약제(스테로이드), 동반 질환, 흡연, 알코올, 류마티스 관절염 등이 원인이 될 수 있고, 골의 재형성 과정에 문제가 일어난 것일 수 있으며, 대부분 증상이 없지만 골절이 생기면 통증이 생기고, 골절이 발생한 부위에 따라 다양한 증상이 나타날 수 있는 것을 의미한다.The “osteoporosis” is a skeletal disease that weakens the strength of bones and causes them to fracture easily. Specifically, genetic factors, early menopause, medications (steroids), concomitant diseases, smoking, alcohol, rheumatoid arthritis, etc. may be the cause, and problems may occur in the bone remodeling process. In most cases, there are no symptoms, but fractures may occur. This means that when this occurs, pain occurs and various symptoms may appear depending on the area where the fracture occurred.
본 발명의 용어, "골의 재형성 과정"은 조골세포와 파골세포에 의해 이루어진다. 조골세포는 새로운 뼈를 생성하는 골 형성 과정에, 파골세포는 낡은 뼈를 파괴하는 골 흡수에 관여하는 것을 의미한다. 구체적으로, 폐경에 의해 여성호르몬의 결핍이 나타나면 이런 골의 재형성과정에 관여하는 조골세포와 파골세포에 직접, 간접적으로 영향을 미쳐 골 손실이 유발된다. 즉, 폐경 후 골의 재형성이 활발해지고 골 흡수 정도가 골 생성 정도보다 많아져 골 손실을 유발하게 된다.As used herein, the “bone remodeling process” is accomplished by osteoblasts and osteoclasts. Osteoblasts are involved in the bone formation process that creates new bone, and osteoclasts are involved in bone resorption, which destroys old bone. Specifically, when female hormone deficiency occurs due to menopause, it directly or indirectly affects osteoblasts and osteoclasts involved in the bone remodeling process, causing bone loss. In other words, after menopause, bone remodeling becomes active and the degree of bone resorption exceeds the degree of bone formation, causing bone loss.
본 발명의 용어, "예방"은 본 발명에 따른 약학 조성물의 투여에 의해 염증의 발병을 억제시키거나 또는 지연시키는 모든 행위를 의미한다.As used herein, the term “prevention” refers to any action that suppresses or delays the onset of inflammation by administering the pharmaceutical composition according to the present invention.
본 발명의 용어, "개선"은 본 발명에 따른 조성물을 투여로 치료되는 상태와 관련된 파라미터, 예를 들면 증상의 정도를 적어도 감소시키는 모든 행위를 의미한다.As used herein, the term "improvement" means any action that results in at least a reduction in the degree of symptoms, for example, parameters related to the condition being treated by administering the composition according to the invention.
본 발명의 용어, "치료"는 상기 약학 조성물의 투여에 의해 염증의 의심 및 발병 개체의 증상이 호전되거나 이롭게 변경되는 모든 행위를 의미한다.As used herein, the term “treatment” refers to any action in which the symptoms of an individual suspected of or suffering from inflammation are improved or beneficially changed by administration of the pharmaceutical composition.
본 발명의 조성물은 약학적으로 허용 가능한 염을 추가로 포함할 수 있다.The composition of the present invention may further include a pharmaceutically acceptable salt.
상기 목적을 달성하기 위한 본 발명의 또 다른 실시 양태는 상기 배양방법으로 배양된 동충하초, 동충하초의 추출물 또는 이의 식품학적으로 허용 가능한 염을 포함하는 면역력 개선 또는 항염용, 암 예방 또는 개선용, 항비만용, 및 골질환 예방 또는 개선용 건강기능식품 조성물을 제공한다. Another embodiment of the present invention to achieve the above object is for improving immunity or anti-inflammatory, preventing or improving cancer, and anti-obesity, including Cordyceps sinensis cultured by the above culture method, an extract of Cordyceps sinensis, or a foodologically acceptable salt thereof. Provides a health functional food composition for use, and preventing or improving bone disease.
상기 목적을 달성하기 위한 본 발명의 다른 실시 양태는 본 발명에 따른 동충하초, 동충하초의 추출물은 우수한 염증 억제, 항암, 항비만 및 골질환 개선 및 예방 효과를 나타내므로, 염증 예방 또는 개선, 항암, 항비만, 골질환 예방 및 개선을 목적으로 식품 조성물에 포함될 수 있으며, 상기 식품 조성물은 일상적으로 섭취하는 것이 가능하기 때문에 염증의 예방 또는 개선, 항암, 항비만, 골질환 예방 및 개선에 대하여 높은 효과를 기대할 수 있다.Another embodiment of the present invention to achieve the above object is that the extract of Cordyceps sinensis and Cordyceps sinensis according to the present invention exhibits excellent anti-inflammatory, anti-cancer, anti-obesity and bone disease improvement and prevention effects, thereby preventing or improving inflammation, anti-cancer and anti-inflammatory effects. It can be included in a food composition for the purpose of preventing and improving obesity and bone disease, and since the food composition can be consumed on a daily basis, it has a high effect on preventing or improving inflammation, anti-cancer, anti-obesity, and preventing and improving bone disease. You can expect it.
이때, 상기 "동충하초", "염증", "항암", "비만", "골질환", "개선" 및 "예방"에 대한 설명은 상기 서술한 바와 같다.At this time, the descriptions of “Cordyceps sinensis”, “inflammation”, “anti-cancer”, “obesity”, “bone disease”, “improvement” and “prevention” are as described above.
본 발명의 용어, "건강기능식품"은 건강기능식품에 관한 법률 제6727호에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 의미하며, '기능성'은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻는 것을 의미한다. 한편, 건강식품은 일반식품에 비해 적극적인 건강유지나 증진 효과를 가지는 식품을 의미하고, 건강보조식품은 건강 보조 목적의 식품을 의미하는데, 경우에 따라, 건강기능식품, 건강식품, 건강보조식품의 용어는 혼용될 수 있다.The term "health functional food" in the present invention refers to food manufactured and processed using raw materials or ingredients with functionality useful to the human body in accordance with Act No. 6727 on Health Functional Food, and "functionality" refers to the structure of the human body. It means controlling nutrients for functions or obtaining useful effects for health purposes such as physiological effects. Meanwhile, health food refers to food that has a more active health maintenance or promotion effect compared to general food, and health supplement refers to food for health supplement purposes. In some cases, the terms health functional food, health food, and health supplement food are used. can be used interchangeably.
본 발명의 동충하초, 동충하초의 추출물 또는 이의 식품학적으로 허용 가능한 염은 그대로 첨가되거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다.Cordyceps sinensis, extracts of Cordyceps sinensis, or food-acceptable salts thereof of the present invention may be added as is or used together with other foods or food ingredients, and may be used appropriately according to conventional methods.
본 발명의 식품은 당 업계에서 통상적으로 사용되는 방법에 의하여 제조 가능하며, 상기 제조 시에는 당 업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. 구체적으로, 상기 식품 조성물은 생리학적으로 허용 가능한 담체를 추가로 포함할 수 있는데, 담체의 종류는 특별히 제한되지 않으며 당해 기술 분야에서 통상적으로 사용되는 담체라면 어느 것이든 사용할 수 있다. 또한, 상기 식품 조성물은 방부제, 살균제, 산화방지제, 착색제, 발색제, 표백제, 조미료, 감미료, 향료, 팽창제, 강화제, 유화제, 증점제, 피막제, 검기초제, 거품억제제, 용제, 개량제 등의 식품 첨가물을 포함할 수 있다. 상기 첨가물은 식품의 종류에 따라 선별되고 적절한 양으로 사용될 수 있다.The food of the present invention can be manufactured by methods commonly used in the industry, and can be manufactured by adding raw materials and ingredients commonly added in the industry. Specifically, the food composition may further include a physiologically acceptable carrier. The type of carrier is not particularly limited, and any carrier commonly used in the art can be used. In addition, the food composition contains food additives such as preservatives, disinfectants, antioxidants, colorants, coloring agents, bleaches, seasonings, sweeteners, flavorings, leavening agents, strengthening agents, emulsifiers, thickening agents, coating agents, gum base agents, foam suppressants, solvents, and improvers. It can be included. The additives can be selected depending on the type of food and used in an appropriate amount.
또한, 상기 식품의 제형은 식품으로 인정되는 제형이면 제한 없이 제조될 수 있다. 본 발명의 식품용 조성물은 다양한 형태의 제형으로 제조될 수 있으며, 일반약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고 휴대성이 뛰어나므로, 본 발명의 식품은 염증의 예방 또는 개선, 항암, 항비만, 골질환 예방 또는 개선의 효과를 증진시키기 위한 보조제로 섭취가 가능하다.Additionally, the food formulation can be manufactured without limitation as long as it is a formulation recognized as a food. The food composition of the present invention can be manufactured in various types of formulations, and unlike general drugs, it is made from food as a raw material and has the advantage of having no side effects that may occur when taking the drug for a long period of time and is highly portable, so the present invention Foods can be consumed as supplements to enhance the effects of preventing or improving inflammation, anti-cancer, anti-obesity, and preventing or improving bone disease.
본 발명의 동충하초 또는 이의 식품학적으로 허용 가능한 염은 면역력 개선 또는 항염, 암 예방 또는 개선, 항비만, 및 골질환 예방 또는 개선 효과를 나타낼 수 있다면 식품 조성물에 다양한 중량%로 포함될 수 있다. 구체적으로 식품 조성물의 총 중량대비 0.00001 내지 100 중량% 또는 0.01 내지 80 중량%로 포함될 수 있으나, 이에 제한되지 않는다. 건강 및 위생을 목적으로 장기간 섭취할 경우에는 상기 범위 이하의 함량을 포함할 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다.Cordyceps sinensis or a food-acceptable salt thereof of the present invention may be included in various weight percentages in a food composition if it can exhibit the effects of improving immunity or anti-inflammatory, preventing or improving cancer, anti-obesity, and preventing or improving bone disease. Specifically, it may be included in an amount of 0.00001 to 100% by weight or 0.01 to 80% by weight based on the total weight of the food composition, but is not limited thereto. When consumed for a long period of time for health and hygiene purposes, the content may be below the above range. Since there is no problem in terms of safety, the active ingredient may be used in amounts above the above range.
상기 목적을 달성하기 위한 본 발명의 또 다른 실시 양태는 상기 배양방법으로 배양된 동충하초, 동충하초의 추출물 또는 이의 식품학적으로 허용 가능한 염을 포함하는 면역력 개선 또는 항염용, 암 예방 또는 개선용, 항비만용, 및 골질환 예방 또는 개선용 사료 조성물을 제공한다. Another embodiment of the present invention to achieve the above object is for improving immunity or anti-inflammatory, preventing or improving cancer, and anti-obesity, including Cordyceps sinensis cultured by the above culture method, an extract of Cordyceps sinensis, or a foodologically acceptable salt thereof. Provides a feed composition for preventing or improving bone disease.
이때, 상기 "동충하초", "식품학적으로 허용 가능한 염", "항염증", "염증", "항암", "비만", "골질환", "예방" 및 "개선"에 대한 설명은 상기에서 서술한 바와 같다.At this time, the descriptions of “Cordyceps sinensis”, “foodologically acceptable salt”, “anti-inflammatory”, “inflammation”, “anti-cancer”, “obesity”, “bone disease”, “prevention” and “improvement” are as above. It is the same as described in .
본 발명에 따른 동충하초, 동충하초의 추출물 또는 이의 식품학적으로 허용 가능한 염은 우수한 염증 억제, 항암, 항비만, 골질환 예방 및 개선 효과를 나타내므로, 면역력 개선 또는 항염, 암 예방 또는 개선, 항비만, 및 골질환 예방 또는 개선을 목적으로 사료 조성물에 포함될 수 있으며, 상기 사료 조성물은 동물이 일상적으로 섭취하는 것이 가능하기 때문에 염증의 예방 또는 개선, 항암에 대하여 높은 효과를 기대할 수 있다.Cordyceps sinensis, an extract of Cordyceps sinensis, or a food-acceptable salt thereof according to the present invention exhibits excellent anti-inflammatory, anti-cancer, anti-obesity, and bone disease prevention and improvement effects, thereby improving or anti-inflammatory immunity, preventing or improving cancer, anti-obesity, And it can be included in a feed composition for the purpose of preventing or improving bone disease. Since the feed composition can be consumed by animals on a daily basis, it can be expected to be highly effective in preventing or improving inflammation and anti-cancer.
본 발명의 용어, "사료"는 동물이 먹고, 섭취하며, 소화시키기 위한 또는 이에 적당한 임의의 천연 또는 인공 규정식, 한끼식 등 또는 상기 한끼식의 성분을 의미한다. 상기 사료의 종류는 특별히 제한되지 아니하며, 당해 기술 분야에서 통상적으로 사용되는 사료를 사용할 수 있다. 상기 사료의 비제한적인 예로는, 곡물류, 근과류, 식품 가공 부산물류, 조류, 섬유질류, 제약 부산물류, 유지류, 전분류, 박류 또는 곡물 부산물류 등과 같은 식물성 사료; 단백질류, 무기물류, 유지류, 광물성류, 유지류, 단세포 단백질류, 동물성 플랑크톤류 또는 음식물 등과 같은 동물성사료를 들 수 있다. 이들은 단독으로 사용되거나 2종 이상을 혼합하여 사용될 수 있다.As used herein, the term "feed" means any natural or artificial diet, meal, etc., or a component of the meal, for or suitable for eating, ingestion, and digestion by animals. The type of feed is not particularly limited, and feed commonly used in the art can be used. Non-limiting examples of the feed include plant feeds such as grains, roots and fruits, food processing by-products, algae, fiber, pharmaceutical by-products, oils and fats, starches, cucurbits or grain by-products; Examples include animal feeds such as proteins, inorganic substances, fats and oils, minerals, oils and fats, single-cell proteins, zooplanktons or foods. These may be used alone or in combination of two or more types.
상기 목적을 달성하기 위한 본 발명의 또 다른 실시 양태는 상기 배양방법으로 배양된 동충하초, 동충하초의 추출물 또는 이의 약학적으로 허용 가능한 염을 포함하는 면역력 개선 또는 항염용, 암 예방 또는 개선용, 항비만용, 및 골질환 예방 또는 개선용 약학 조성물을 제공한다. Another embodiment of the present invention to achieve the above object is for improving immunity or anti-inflammatory purposes, preventing or improving cancer, and anti-obesity, including Cordyceps sinensis cultured by the above culture method, an extract of Cordyceps sinensis or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof. Provides a pharmaceutical composition for treating and preventing or improving bone diseases.
본 발명의 약학 조성물은, 약학적으로 허용 가능한 담체, 부형제 또는 희석제를 추가로 포함할 수 있는데, 상기 담체는 비자연적 담체(non-naturallyoccuring carrier)를 포함할 수 있다.The pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier, excipient, or diluent, and the carrier may include a non-naturally occurring carrier.
본 발명의 용어, "약학적으로 허용 가능한 염"은 양이온과 음이온이 정전기적 인력에 의해 결합하고 있는 물질인 염 중에서도 약학적으로 사용될 수 있는 형태의 염을 의미하며, 통상적으로 금속염, 유기염기와의 염, 무기산과의 염, 유기산과의 염, 염기성 또는 산성 아미노산과의 염 등이 될 수 있다. 예를 들어, 금속염으로는 알칼리 금속염(나트륨염, 칼륨염 등), 알칼리 토금속염(칼슘염, 마그네슘염, 바륨염 등), 알루미늄염 등이 될 수 있고; 유기염기와의 염으로는 트리에틸아민, 피리딘, 피콜린, 2,6-루티딘, 에탄올아민, 디에탄올아민, 트리에탄올아민, 시클로헥실아민, 디시클로헥실아민, N,N-디벤질에틸렌디아민 등과의 염이 될 수 있으며; 무기산과의 염으로는 염산, 브롬화수소산, 질산, 황산, 인산 등과의 염이 될 수 있고; 유기산과의 염으로는 포름산, 아세트산, 트리플루오로아세트산, 프탈산, 푸마르산, 옥살산, 타르타르산, 말레인산, 시트르산, 숙신산, 메탄술폰산, 벤젠술폰산, p-톨루엔술폰산 등과의 염이 될 수 있으며; 염기성 아미노산과의 염으로는 아르기닌, 라이신, 오르니틴 등과의 염이 될 수 있고; 산성 아미노산과의 염으로는 아스파르트산, 글루탐산 등과의 염이 될 수 있다.As used herein, the term "pharmaceutically acceptable salt" refers to a salt that can be used pharmaceutically among salts that are substances in which cations and anions are combined by electrostatic attraction, and are usually metal salts, organic bases, and It can be a salt of, a salt with an inorganic acid, a salt with an organic acid, a salt with a basic or acidic amino acid, etc. For example, the metal salt may be an alkali metal salt (sodium salt, potassium salt, etc.), an alkaline earth metal salt (calcium salt, magnesium salt, barium salt, etc.), an aluminum salt, etc.; Salts with organic bases include triethylamine, pyridine, picoline, 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dicyclohexylamine, and N,N-dibenzylethylenediamine. It may be a salt with, etc.; Salts with inorganic acids may include salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, etc.; Salts with organic acids may include salts with formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid; Salts with basic amino acids may include salts with arginine, lysine, ornithine, etc.; Salts with acidic amino acids can be salts with aspartic acid, glutamic acid, etc.
구체적으로, 상기 약학 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트, 폴리카프로락톤(polycaprolactone), 폴리락틱액시드(Poly Lactic Acid), 폴리-L-락틱액시드(poly-L-lactic acid), 광물유 등을 들 수 있다. 상기 약학 조성물은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있으며, 담체의 형태로는 각종 부정형의 담체, 마이크로 스피어, 나노파이버 등을 포함할 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. 경구투여를 위한 고형 제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형 제제는 상기 추출물과 이의 분획물들에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘 카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 마그네슘 스티레이트, 탈크 같은 윤활제들도 사용될 수 있다. 경구투여를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제 등이 포함될 수 있다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 본 발명의 약학 조성물에 포함된 동충하초 또는 이의 약학적으로 허용 가능한 염의 함량은 특별히 제한되지 않는다.Specifically, carriers, excipients, and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, and calcium. Silicates, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, polycaprolactone, polylactic acid (Poly) Lactic Acid, poly-L-lactic acid, mineral oil, etc. The pharmaceutical composition can be formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injectable solutions according to conventional methods, respectively. The form may include various amorphous carriers, microspheres, nanofibers, etc. When formulated, it can be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations include the extract and its fractions with at least one excipient, such as starch, calcium carbonate, It can be prepared by mixing sucrose, lactose, gelatin, etc. Additionally, in addition to simple excipients, lubricants such as magnesium styrate and talc may also be used. Liquid preparations for oral administration include suspensions, oral solutions, emulsions, and syrups. In addition to the commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. there is. Preparations for parenteral administration may include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, suppositories, etc. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate. The content of Cordyceps sinensis or a pharmaceutically acceptable salt thereof contained in the pharmaceutical composition of the present invention is not particularly limited.
또한, 본 발명의 제18양태는 상기 동충하초의 추출물은 메탄올(MeOH), 물 및 프레타놀(prethano)로 이루어진 군에서 선택된 하나 이상의 추출용매로 추출된 것인, 동충하초의 추출물을 제공한다.In addition, the 18th aspect of the present invention provides an extract of Cordyceps sinensis, wherein the extract of Cordyceps sinensis is extracted with one or more extraction solvents selected from the group consisting of methanol (MeOH), water, and prethano.
본 발명의 용어, "추출물"은 액체 또는 고체 혼합물로부터 용매에 의해 분리된 물질을 의미한다. As used herein, the term “extract” refers to a substance separated by a solvent from a liquid or solid mixture.
상기 추출물은 1μg/ml 내지 10μg/ml 농도로 제조된 것일 수 있으나, 이에 제한되는 것은 아니다.The extract may be prepared at a concentration of 1 μg/ml to 10 μg/ml, but is not limited thereto.
구체적인 일 실시예에서는, 본 발명의 동충하초 배양용 조성물로 배양된 동충하초는 코디세핀 및 베타글루칸 함량이 증진되었고, 이러한 동충하초를 포함하였을 때 NO생성 억제, 사이토카인 생성 억제, 지방세포 분화억제, 및 파골세포 분화 억제 효과를 확인하였다.In a specific example, Cordyceps sinensis cultured with the composition for culturing Cordyceps sinensis of the present invention had an increased content of cordycepin and beta-glucan, and when it contained Cordyceps sinensis, it inhibited NO production, inhibited cytokine production, inhibited adipocyte differentiation, and osteoclasts. The cell differentiation inhibitory effect was confirmed.
더욱 구체적으로, 본 발명의 동충하초를 베타원 품종의 보리를 사용하고 추출용매를 메탄올로 추출할 경우, 다른 품종으로 재배한 경우 및 다른 추출용매로 추출한 추추물 대비, 코디세핀 및 베타글루칸의 함량이 향상되고(실시예 3), 그럼으로 하여 지방세포 분화를 효과적으로 억제시키고(실시예 7) 파골세포 분화 또한 효과적으로 억제(실시예 8)시키는 것을 확인하였다.More specifically, when Cordyceps sinensis of the present invention is extracted using barley of the beta one variety and the extraction solvent is methanol, the content of cordycepin and beta-glucan is higher compared to the extract grown with other varieties and extracted with other extraction solvents. It was confirmed that it was improved (Example 3), thereby effectively suppressing adipocyte differentiation (Example 7) and osteoclast differentiation (Example 8).
따라서, 상기 구체적인 일 실시예를 통하여 본 발명의 동충하초 또는 동충하초의 추출물이 항염, 항암, 항비만, 골질환 예방 및 개선 용도를 가지는 것을 확인할 수 있었으며, 이는 나아가 염증, 비만, 및 골 관련 질환 및 암을 예방 또는 개선, 치료할 수 있는 용도로 사용될 수 있음을 시사한다.Therefore, through the above specific example, it was confirmed that Cordyceps sinensis or an extract of Cordyceps sinensis of the present invention has anti-inflammatory, anti-cancer, anti-obesity, and bone disease prevention and improvement uses, which further contributes to inflammation, obesity, bone-related diseases, and cancer. This suggests that it can be used to prevent, improve, or treat.
본 발명의 동충하초 배양방법으로 배양된 동충하초는 세포독성이 나타나지 않고 동시에 NO생성 억제, 사이토카인 생성 억제, 지방세포 분화 억제, 및 파골세포 분화 억제 효과를 확인하여 항염, 항비만, 골질환 억제 조성물로 사용될 수 있다.Cordyceps sinensis cultured using the Cordyceps sinensis culture method of the present invention does not show cytotoxicity and at the same time has the effects of inhibiting NO production, inhibiting cytokine production, inhibiting adipocyte differentiation, and inhibiting osteoclast differentiation, and is thus used as an anti-inflammatory, anti-obesity, and bone disease-inhibiting composition. can be used
도 1은 본 발명의 동충하초 추출물의 추출용매를 달리하여 추출한 것의 코디세핀 함량을 나타낸 그래프이다.
도 2는 본 발명의 동충하초 추출물에 대한 세포독성을 나타낸 그래프이다.
도 3은 본 발명의 동충하초 추출물의 NO생성 억제 활성을 나타낸 그래프이다.
도 4는 본 발명의 동충하초 추출물의 LPS로 자극된 대식세포의 사이토카인(TNF-α) 함량 억제 효과를 나타낸 그래프이다.
도 5는 본 발명의 동충하초 추출물의 LPS로 자극된 대식세포의 사이토카인(IL-6) 함량 억제 효과를 나타낸 그래프이다.
도 6은 본 발명의 동충하초 추출물의 추출용매별 지방세포 분화 억제 효과를 나타낸 사진이다.
도 7은 본 발명의 동충하초 추출물의 농도별 지방세포 분화 억제 효과를 나타낸 사진이다.
도 8은 본 발명의 동충하초 추출물 1 μg/ml 농도에서의 파골세포 분화 억제 효과를 나타낸 사진이다.
도 9는 본 발명의 동충하초 추출물의 추출용매를 달리하여 추출한 것의 파골세포 분화 억제 효과를 나타낸 사진이다.Figure 1 is a graph showing the cordycepin content of the Cordyceps sinensis extract of the present invention extracted using different extraction solvents.
Figure 2 is a graph showing the cytotoxicity of the Cordyceps sinensis extract of the present invention.
Figure 3 is a graph showing the NO production inhibitory activity of the Cordyceps sinensis extract of the present invention.
Figure 4 is a graph showing the effect of the Cordyceps sinensis extract of the present invention on suppressing the cytokine (TNF-α) content of macrophages stimulated with LPS.
Figure 5 is a graph showing the effect of the Cordyceps sinensis extract of the present invention on suppressing the cytokine (IL-6) content of macrophages stimulated with LPS.
Figure 6 is a photograph showing the effect of the Cordyceps sinensis extract of the present invention on inhibiting adipocyte differentiation by extraction solvent.
Figure 7 is a photograph showing the effect of inhibiting adipocyte differentiation at different concentrations of the Cordyceps sinensis extract of the present invention.
Figure 8 is a photograph showing the inhibitory effect on osteoclast differentiation at a concentration of 1 μg/ml of the Cordyceps sinensis extract of the present invention.
Figure 9 is a photograph showing the effect of inhibiting osteoclast differentiation of the Cordyceps sinensis extract of the present invention extracted using different extraction solvents.
이하, 실시예를 통하여 본 발명을 보다 상세히 설명하고자 한다. 이들 실시예는 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 범위가 이들 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail through examples. These examples are for illustrating the present invention in more detail, and the scope of the present invention is not limited by these examples.
실시예 1: 동충하초 배양 방법Example 1: Cordyceps sinensis culture method
감자하천배지(PDA, 대두분, 설탕, MgSO4, KH2PO4)를 이용하여 상황버섯 원균 및 동충하초 원균을 증식하였다. 감자하천배지(PDA, 대두분, 설탕, MgSO4, KH2PO4), 보리 40g, 소포제를 멸균 유리병에 넣어 21℃에서 진탕 암배양 하여 원균을 증식시켰다. 천마 30g과 보리 40g을 1차로 증숙 및 살균하여 동충하초 자실체 배지를 만들었다. 동충하초 자실체 배지에 동충하초균을 접종하여 진탕하면서 암배양하였다. 동충하초 자실체 배지를 생육실에서 온도 19℃ 내지 21℃, 습도 60% 내지 80%, 조도 1200Lux 내지 1300Lux의 조건을 유지하여 자실체의 평균길이가 4 내지 6cm까지 44일 동안 생육 재배하였다.Potato stream medium (PDA, soybean meal, sugar, MgSO 4 , KH 2 PO 4 ) was used to grow Phellodendron fungi and Cordyceps sinensis protobacteria. Potato stream medium (PDA, soybean meal, sugar, MgSO 4 , KH 2 PO 4 ), 40 g of barley, and antifoam were placed in a sterilized glass bottle and cultured in the dark with shaking at 21°C to grow the protobacteria. Cordyceps sinensis fruiting body medium was prepared by first steaming and sterilizing 30g of dried hemp and 40g of barley. Cordyceps sinensis fruiting body medium was inoculated with Cordyceps sinensis and cultured in the dark while shaking. Cordyceps sinensis fruiting body medium was grown and cultivated in a growth room under conditions of temperature 19°C to 21°C, humidity 60% to 80%, and illumination intensity of 1200 Lux to 1300 Lux for 44 days until the average fruiting body length was 4 to 6 cm.
실시예 2: 동충하초 추출물 제조방법Example 2: Cordyceps sinensis extract manufacturing method
상기 실시예 1의 동충하초를 45℃에서 건조한 후 분쇄하였다. 동충하초분말 100g을 1L 50% MeOH, 물, 프레타놀(prethanol, 주정, 에탄올)로 각각 추출용매를 다르게 하여 3회 추출해 여과한 후 회전진공증발장치(Eyela Co., Ltd., Shanghai, China)를 이용하여 농축하였다.Cordyceps sinensis of Example 1 was dried at 45°C and then ground. 100g of Cordyceps sinensis powder was extracted three times with 1L 50% MeOH, water, and pretanol (prethanol, alcohol, ethanol) using different extraction solvents, filtered, and then filtered using a rotary vacuum evaporator (Eyela Co., Ltd., Shanghai, China). It was concentrated using
실시예 3: 동충하초 추출물의 코디세핀 및 베타글루칸 함량 분석Example 3: Analysis of cordycepin and beta-glucan content of Cordyceps sinensis extract
상기 실시예 2의 동충하초 추출물을 하기 표 1과 같이, 보리의 품종을 달리하여 제조하여 액체크로마토그래피(LC)로 코디세핀, 총 글루칸 함량, 알파글루칸 및 베타글루칸 함량을 분석하였다.The Cordyceps sinensis extract of Example 2 was prepared from different barley varieties, as shown in Table 1 below, and analyzed for cordycepin, total glucan content, alpha-glucan, and beta-glucan content by liquid chromatography (LC).
표 1 및 도 1에 나타난 바와 같이, 보리의 품종은 새쌀(B2-1), 새찰쌀(B2-2), 누리찰(B2-6) 및 베타원(B2-10) 중 새찰쌀 또는 베타원에서 코디세핀의 함량이 가장 높았고(표 1), 물, 프레타놀 및 50% MeOH로 추출한 동충하초 추출물 중 50% MeOH로 추출한 동충하초 추출물이 코디세핀 함량이 가장 높았다(도 1). 따라서, 본 발명의 동충하초는 새찰 쌀 및 베타원 품종으로 재배되고 50% MeOH로 추출한 동충하초 추출물이 항염 효과에 가장 우수한 결과를 나타내는 것을 확인하였다.As shown in Table 1 and Figure 1, the varieties of barley are Saechal (B2-1), Saechal (B2-2), Nurichal (B2-6), and Betawon (B2-10). The cordycepin content was the highest (Table 1), and among the Cordyceps sinensis extracts extracted with water, pretanol, and 50% MeOH, the Cordyceps sinensis extract extracted with 50% MeOH had the highest cordycepin content (Figure 1). Therefore, it was confirmed that the Cordyceps sinensis of the present invention is cultivated with Saechal rice and Beta One varieties, and that the Cordyceps sinensis extract extracted with 50% MeOH shows the best anti-inflammatory effect.
실시예 4: 세포독성 분석Example 4: Cytotoxicity assay
상기 실시예 3과 같이, 보리의 품종을 달리하여 재배한 동충하초를 농도별로 추출물을 제조하고, 이의 세포 생존율을 측정하여 세포독성을 분석하였다.As in Example 3, extracts of Cordyceps sinensis cultivated with different varieties of barley were prepared at different concentrations, and their cell viability was measured and cytotoxicity was analyzed.
도 2에 나타난 바와 같이, 본 발명의 동충하초 추출물(B2-1, B2-2, B2-6, B2-10)은 각 농도에서(1, 3, 10μg/ml) 세포 생존율을 측정결과 세포독성을 나타내지 않는 것을 확인할 수 있다.As shown in Figure 2, the Cordyceps sinensis extract (B2-1, B2-2, B2-6, B2-10) of the present invention showed cytotoxicity as a result of measuring cell viability at each concentration (1, 3, and 10 μg/ml). You can check that it is not displayed.
실시예 5: NO생성 억제 분석Example 5: NO production inhibition analysis
RAW 264.7 대식세포는 5×104 cells/well로 96 well plate에 분주하여 12~20시간 배양하고 1 μg/mL의 LPS와 주정추출물을 농도별(1, 3, 10 μg/mL)로 처리하여 24시간 배양하였다. 배양이 끝난 후, 상층액 100 μL를 얻어 동량의 그리스(griess) 시약(1% sulfanilamide: 0.1% naphthylenthylenediamine = 1:1)을 첨가하여 실온에서 10분간 반응시켰다. 반응액은 microplate reader(VERSAmax, Molecular Devices, LLC.)를 이용하여 550 nm에서 흡광도를 측정하였다. 아질산염(Nitrite)의 농도는 아질산 나트륨(sodium nitrite)(FUJIFILM Wako Pure Chemical Co., Osaka, Japan)을 표준물질로 하여 얻은 표준곡선에 대입하여 산출하였다.RAW 264.7 macrophages were distributed in a 96 well plate at 5 cultured for some time. After incubation, 100 μL of the supernatant was obtained, an equal amount of Griess reagent (1% sulfanilamide: 0.1% naphthylenthylenediamine = 1:1) was added, and the mixture was reacted at room temperature for 10 minutes. The absorbance of the reaction solution was measured at 550 nm using a microplate reader (VERSAmax, Molecular Devices, LLC.). The concentration of nitrite was calculated by substituting it into a standard curve obtained using sodium nitrite (FUJIFILM Wako Pure Chemical Co., Osaka, Japan) as a standard material.
도 3에 나타난 바와 같이, NO 생성량은 LPS 무처리군에 비해 LPS 단독 처리군에서 1845배 증가되어 과도한 염증반응이 일어났다. 그러나 본 발명의 동충하초 추출물(B2-1, B2-2, B2-6, B2-10)을 1, 3, 10 μg/mL로 처리하였을 때 LPS 단독 처리군에 비하여 농도 의존적으로 NO생성을 억제하였으며 10 μg/mL로 처리하였을 때 각각 15.76%, 23.88%, 26.29%, 36.09%의 NO 생성을 억제하여 보리품종 베타원으로 재배한 동충하초의 추출물(B2-10)의 항염효과가 가장 우수한 것을 확인하였다.As shown in Figure 3, the amount of NO production increased 1845 times in the LPS-only treated group compared to the LPS-untreated group, resulting in an excessive inflammatory response. However, when treated with the Cordyceps sinensis extract (B2-1, B2-2, B2-6, B2-10) of the present invention at 1, 3, and 10 μg/mL, NO production was suppressed in a concentration-dependent manner compared to the LPS-only treatment group. When treated at 10 μg/mL, NO production was suppressed by 15.76%, 23.88%, 26.29%, and 36.09%, respectively, confirming that the extract of Cordyceps sinensis (B2-10) grown with barley variety Beta One had the best anti-inflammatory effect. .
실시예 6: LPS로 자극된 대식세포의 사이토카인 활성 분석Example 6: Cytokine activity analysis of macrophages stimulated with LPS
RAW 264.7 대식세포는 5×104 cells/well로 96 well plate에 분주하여 12~20시간 배양한 후 1 μg/mL의 LPS와 100, 300, 500 μg/mL의 BTE를 처리하여 24시간 배양하였다. 세포 배양액 내의 TNF-α 및 IL-6 사이토카인 함량은 마우스 듀오셋 효소결합면역흡착측정법(mouse Duoset enzyme-linked immunosorbent assay)(ELISA, R&D Systems Inc., Minneapolis, MN, USA)을 사용하여 정량하였다. 100 μL의 항체 포획(capture antibody)을 마이크로플레이트(microplate)에 분주하여 하룻밤 동안 코팅한 후 0.05% Tween 20이 포함된 인산완충식염수(phospho buffered saline)(PBS; PBST)으로 세척하고 1% 소혈청알부민(bovine serum albumin)을 포함한 PBS로 blocking 한 후 PBST()로 세척하고 시료를 분주하여 실온에서 2시간 동안 반응시켰다. 반응 후, PBST로 세척하고 검출항체(detection antibody)를 처리하여 실온에서 2시간 반응시켜 PBST로 세척하고 스트렙타비딘-스테라디시 과산화효소 결합액(streptavidin-horseradish peroxidase conjugate)을 분주하여 실온에서 20분간 반응시킨 후, PBST로 세척하고 기질용액을 넣어 실온에서 20분간 암실반응 시켰으며, 반응 정지용액을 첨가하여 반응을 종료하고 microplate reader(VERSAmax, Molecular Devices, LLC.)를 이용하여 각각 450 nm와 540 nm에서 흡광도를 측정하였다.RAW 264.7 macrophages were distributed in a 96 well plate at 5 × 104 cells/well and cultured for 12 to 20 hours, then treated with 1 μg/mL of LPS and 100, 300, and 500 μg/mL of BTE and cultured for 24 hours. The content of TNF-α and IL-6 cytokines in cell culture was quantified using mouse Duoset enzyme-linked immunosorbent assay (ELISA, R&D Systems Inc., Minneapolis, MN, USA). . 100 μL of capture antibody was dispensed onto a microplate and coated overnight, then washed with phospho buffered saline (PBS; PBST) containing 0.05% Tween 20, and 1% bovine serum. After blocking with PBS containing bovine serum albumin, the sample was washed with PBST (), aliquoted, and reacted at room temperature for 2 hours. After reaction, washed with PBST, treated with detection antibody, reacted at room temperature for 2 hours, washed with PBST, dispensed with streptavidin-horseradish peroxidase conjugate, and incubated at room temperature for 20 hours. After reacting for a minute, washing with PBST, adding the substrate solution and reacting in the dark at room temperature for 20 minutes, the reaction was terminated by adding the reaction stop solution, and using a microplate reader (VERSAmax, Molecular Devices, LLC.) at 450 nm and 450 nm, respectively. Absorbance was measured at 540 nm.
도 4 내지 도 5에 나타난 바와 같이, 발명의 동충하초 추출물(B2-1, B2-2, B2-6, B2-10)은 각 농도에서(1, 3, 10μg/ml) LPS 단독 처리군에 비하여 10 μg/mL 농도에서 사이토카인 TNF-α 함량이 각각 54.96%, 61.63%, 61.78%, 75.98% 감소하였고, 사이토카인 IL-6 함량은 각각 35.34%, 50.73%, 61.45%, 92.42% 억제하는 것을 확인하여 농도의존적으로 항염효과를 제공하는 것을 확인하였고, 보리품종 베타원으로 재배한 동충하초의 추출물(B2-10)의 항염효과가 가장 우수한 것을 확인하였다. As shown in Figures 4 and 5, the Cordyceps sinensis extract (B2-1, B2-2, B2-6, B2-10) of the present invention has a higher concentration than the LPS-only treatment group at each concentration (1, 3, and 10 μg/ml). At a concentration of 10 μg/mL, the cytokine TNF-α content was reduced by 54.96%, 61.63%, 61.78%, and 75.98%, respectively, and the cytokine IL-6 content was inhibited by 35.34%, 50.73%, 61.45%, and 92.42%, respectively. It was confirmed that it provides an anti-inflammatory effect in a concentration-dependent manner, and it was confirmed that the extract of Cordyceps sinensis (B2-10) grown with barley variety Beta One had the best anti-inflammatory effect.
실시예 7: 지방세포 분화 억제 분석Example 7: Adipocyte differentiation inhibition assay
상기 표 1과 같이 보리품종(새쌀 B2-1, 새찰쌀 B2-2, 누리찰 B2-6, 베타원 B2-10)을 달리하고, 상기 실시예 2와 같이 추출용액을 각각 다르게 하여 본 발명의 동충하초 추출물을 제조하였다. 이렇게 제조한 추출물을 각 농도별로(1, 3, 10μg/ml) 지방전구세포에 첨가하고, 지방전구세포에 지방세포를 분화시키고, 분화된 세포를 oil-red 염색법으로 염색하여 지방세포내의 지방을 염색한 다음 현미경하에서 염색된 지방의 수준을 비교하였다. 이때, 음성대조군으로는 분화되지 않은 지방전구세포(Negative)를 사용하고, 양성대조군으로는 분화된 지방전구세포(Positive)를 사용하였다.As shown in Table 1 above, the barley varieties (new rice B2-1, new glutinous rice B2-2, Nurichal B2-6, Beta One B2-10) were varied, and the extraction solutions were different as in Example 2 above to obtain the results of the present invention. Cordyceps sinensis extract was prepared. The extract prepared in this way was added to the preadipocytes at each concentration (1, 3, and 10μg/ml), differentiated the preadipocytes into adipocytes, and stained the differentiated cells with oil-red staining to determine the fat in the adipocytes. After staining, the levels of stained fat were compared under a microscope. At this time, undifferentiated preadipocytes (Negative) were used as a negative control, and differentiated preadipocytes (Positive) were used as a positive control.
도 6에 나타난 바와 같이, 본 발명의 추출물 농도 10μg/ml 에서 추출용매(50% MeOH, 물, 프레타놀)를 다르게 하여 지방세포 분화 억제효과를 살펴보았을 때, 50% MeOH 추출용매로 추출한 동충하초 추출물이 양성대조군 대비 가장 우수하게 지방세포 분화를 억제 하는 것을 확인할 수 있었다. 또한, 항암제로 알려진 코디세핀(cordycepin)(10μg/ml)대비 본 발명의 동충하초 추출물이 지방세포 분화 억제에 효과가 우수하고, 혈당강화 및 콜레스테롤 저하에 효과가 있는 것으로 알려진 페룰산(Ferulic acid)대비 본 발명의 동충하초 추출물이 지방세포 분화 억제 효과가 우수한 것을 확인할 수 있었다.As shown in Figure 6, when examining the effect of inhibiting adipocyte differentiation by using different extraction solvents (50% MeOH, water, pretanol) at a concentration of 10 μg/ml of the extract of the present invention, the Cordyceps sinensis extract extracted with 50% MeOH extraction solvent It was confirmed that it suppressed adipocyte differentiation most excellently compared to the positive control group. In addition, compared to cordycepin (10 μg/ml), which is known as an anticancer agent, the Cordyceps sinensis extract of the present invention is more effective in suppressing adipocyte differentiation, and compared to ferulic acid, which is known to be effective in strengthening blood sugar and lowering cholesterol. It was confirmed that the Cordyceps sinensis extract of the present invention had an excellent effect of inhibiting adipocyte differentiation.
도 7에 나타난 바와 같이, 본 발명의 추출물은 농도 의존적으로, 지방분화를 억제하였고, 보리품종 베타원으로 재배한 동충하초의 추출물(B2-10)의 지방세포 분화 억제 효과가 가장 우수한 것을 확인하였다. As shown in Figure 7, the extract of the present invention inhibited adipocyte differentiation in a concentration-dependent manner, and it was confirmed that the extract of Cordyceps sinensis (B2-10) grown with barley variety beta-one had the best effect on inhibiting adipocyte differentiation.
실시예 8: 파골세포 분화 억제 분석Example 8: Osteoclast differentiation inhibition assay
파골 전구세포에 대식세포증식자극인자로 배양하여 대식세포로 분화 및 파골세포 분화 유도 사이토카인을 첨가하여 분화를 유도시키고, 상기 실시예 7과 같이 제조된 본 발명의 동충하초 추출물을 첨가하였다. 파골세포 분화 억제를 분석하기 위해, 파골세포 분화 관련 분자마커를 염색하여 광학현미경으로 사진을 찍어 비교하였다. 이때, 음성대조군으로는 분화되지 않은 파골세포(Negative)를 사용하고, 양성대조군으로는 분화된 파골세포(Positive)를 사용하였다.Osteoclast progenitor cells were cultured with macrophage proliferation stimulating factor to differentiate into macrophages and osteoclast differentiation-inducing cytokines were added to induce differentiation, and the Cordyceps sinensis extract of the present invention prepared as in Example 7 was added. To analyze the inhibition of osteoclast differentiation, molecular markers related to osteoclast differentiation were stained and photographs were taken and compared using an optical microscope. At this time, undifferentiated osteoclasts (Negative) were used as the negative control group, and differentiated osteoclasts (Positive) were used as the positive control group.
도 8에 나타난 바와 같이, 본 발명의 동충하초 추출물은 1μg/ml 농도에서도 파골세포 분화 억제 효과를 나타내었고, 도 9에 나타난 바와 같이, 50% MeOH 추출용매로 추출한 동충하초 추출물이 양성대조군 대비 가장 우수하게 파골세포 분화를 억제 하는 것을 확인할 수 있었다.As shown in Figure 8, the Cordyceps sinensis extract of the present invention showed an inhibitory effect on osteoclast differentiation even at a concentration of 1 μg/ml, and as shown in Figure 9, the Cordyceps sinensis extract extracted with 50% MeOH extraction solvent was the most excellent compared to the positive control. It was confirmed that osteoclast differentiation was inhibited.
본 발명의 실시예 1 내지 실시예 8을 종합하면, 본 발명의 동충하초 추출물은 세포독성이 나타나지 않고 동시에 NO생성 억제, 사이토카인 생성 억제, 지방세포 분화 억제, 및 파골세포 분화 억제능력을 보여주어 항염 효과, 항비만 효과, 골질환 억제 효과를 나타내는 것을 확인할 수 있다.Summarizing Examples 1 to 8 of the present invention, the Cordyceps sinensis extract of the present invention does not exhibit cytotoxicity and at the same time shows the ability to inhibit NO production, inhibit cytokine production, inhibit adipocyte differentiation, and inhibit osteoclast differentiation, thereby providing anti-inflammatory properties. It can be confirmed that it has anti-obesity effects and bone disease suppression effects.
이상의 설명으로부터, 본 발명이 속하는 기술분야의 당업자는 본 발명이 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 이와 관련하여, 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로 이해해야만 한다. 본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허 청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.From the above description, those skilled in the art to which the present invention pertains will understand that the present invention can be implemented in other specific forms without changing its technical idea or essential features. In this regard, the embodiments described above should be understood in all respects as illustrative and not restrictive. The scope of the present invention should be construed as including the meaning and scope of the patent claims described below rather than the detailed description above, and all changes or modified forms derived from the equivalent concept thereof are included in the scope of the present invention.
Claims (28)
천마를 유효성분으로 포함하는, 동충하초 배양용 조성물로서,
상기 동충하초 배양용 조성물은 코디세핀 함량을 향상시키는 것이 특징인, 동충하초 배양용 조성물.
Saechal rice or Beta One; and
A composition for cultivating Cordyceps sinensis, comprising Cheonma as an active ingredient,
The composition for culturing Cordyceps sinensis is characterized in that it improves the cordycepin content.
상기 새찰쌀 또는 베타원은 동충하초 배양용 조성물 대비 50 중량% 내지 80 중량%로 포함하는 것인, 동충하초 배양용 조성물.
According to paragraph 1,
A composition for cultivating Cordyceps sinensis, wherein the saechal rice or betaone is contained in an amount of 50% to 80% by weight compared to the composition for culturing Cordyceps sinensis.
상기 천마는 동충하초 배양용 조성물 대비 20 중량% 내지 50 중량%로 포함하는 것인, 동충하초 배양용 조성물.
According to paragraph 1,
A composition for cultivating Cordyceps sinensis, which contains 20% to 50% by weight of the Chunma relative to the composition for culturing Cordyceps sinensis.
상기 동충하초 배양용 조성물은 코디세핀 및 베타글루칸의 함량을 향상시키는 것이 특징인, 동충하초 배양용 조성물.
According to paragraph 1,
The composition for culturing Cordyceps sinensis is characterized by improving the content of cordycepin and beta-glucan.
천마를 유효성분으로 포함한 배지로 배양하여 동충하초 자실체를 생성하는 제1단계; 및
상기 동충하초 자실체를 생육재배하는 제2단계;를 포함하는 동충하초 배양방법.
Cordyceps sinensis strain Saechal Rice or Beta One; and
A first step of producing Cordyceps sinensis fruiting bodies by culturing them in a medium containing Cheonma as an active ingredient; and
A Cordyceps sinensis culturing method comprising a second step of growing and cultivating the Cordyceps sinensis fruiting body.
천마를 유효성분으로 포함하는, 코디세핀 및 베타글루칸의 함량 증진용 조성물.
Saechal rice or Beta One; and
A composition for increasing the content of cordycepin and beta-glucan, comprising Cheonma as an active ingredient.
상기 새찰쌀 또는 베타원은 상기 배지 대비 50 중량% 내지 80 중량%로 포함하는 것인, 동충하초 배양방법.
According to clause 6,
A method of cultivating Cordyceps sinensis, wherein the new glutinous rice or beta source is included in an amount of 50% to 80% by weight relative to the medium.
상기 천마는 상기 배지 대비 20 중량% 내지 50 중량%로 포함하는 것인, 동충하초 배양방법.
According to clause 6,
A method of cultivating Cordyceps sinensis, wherein the Cheonma contains 20% to 50% by weight compared to the medium.
상기 방법은 코디세핀 및 베타글루칸의 함량을 향상시키는 것이 특징인, 동충하초 배양방법.
According to clause 6,
The method is a Cordyceps sinensis culturing method characterized by improving the content of cordycepin and beta-glucan.
천마를 유효성분으로 포함한 배지로 배양하여 동충하초 자실체를 생성하는 제1단계; 및
상기 동충하초 자실체를 생육재배하는 제2단계;를 포함하는 동충하초의 코디세핀 또는 베타글루칸 증진방법.
Cordyceps sinensis strain Saechal Rice or Beta One; and
A first step of producing Cordyceps sinensis fruiting bodies by culturing them in a medium containing Cheonma as an active ingredient; and
A method for enhancing cordycepin or beta-glucan of Cordyceps sinensis comprising a second step of growing and cultivating the fruiting body of Cordyceps sinensis.
Cordyceps sinensis cultured by the culture method according to any one of claims 6 and 8 to 10.
A health functional food composition for improving immunity comprising the extract of Cordyceps sinensis of claim 13 as an active ingredient.
An anti-inflammatory health functional food composition containing the extract of Cordyceps sinensis of claim 13 as an active ingredient.
A health functional food composition for preventing or improving cancer comprising the extract of Cordyceps sinensis of claim 13 as an active ingredient.
A health functional food composition for anti-obesity comprising the extract of Cordyceps sinensis of claim 13 as an active ingredient.
A health functional food composition for preventing or improving bone disease containing Cordyceps sinensis of paragraph 13 as an active ingredient.
An anti-inflammatory pharmaceutical composition comprising the extract of Cordyceps sinensis of claim 13 as an active ingredient.
An anti-inflammatory feed composition comprising the extract of Cordyceps sinensis of claim 13 as an active ingredient.
A pharmaceutical composition for preventing or improving cancer comprising the extract of Cordyceps sinensis of claim 13 as an active ingredient.
A feed composition for preventing or improving cancer comprising the extract of Cordyceps sinensis of claim 13 as an active ingredient.
A pharmaceutical composition for anti-obesity comprising the extract of Cordyceps sinensis of claim 13 as an active ingredient.
An anti-obesity feed composition comprising the extract of Cordyceps sinensis of claim 13 as an active ingredient.
A pharmaceutical composition for preventing or improving bone disease comprising the extract of Cordyceps sinensis of claim 13 as an active ingredient.
A feed composition for preventing or improving bone disease comprising the extract of Cordyceps sinensis of claim 13 as an active ingredient.
The health functional food composition according to claim 14, wherein the extract of Cordyceps sinensis is extracted with one or more extraction solvents selected from the group consisting of methanol (MeOH), water, and pretanol (prethanol).
상기추출물은 1μg/ml 내지 10μg/ml 농도로 제조된 것인, 건강기능식품 조성물.
According to clause 27,
The extract is a health functional food composition prepared at a concentration of 1 μg/ml to 10 μg/ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200178747A KR102636200B1 (en) | 2020-12-18 | 2020-12-18 | Composition for cultivating cordyceps sinensis containing barley and cheonma as active ingredients and method for culturing cordyceps sinensis using the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200178747A KR102636200B1 (en) | 2020-12-18 | 2020-12-18 | Composition for cultivating cordyceps sinensis containing barley and cheonma as active ingredients and method for culturing cordyceps sinensis using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20220088078A KR20220088078A (en) | 2022-06-27 |
| KR102636200B1 true KR102636200B1 (en) | 2024-02-14 |
Family
ID=82246977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200178747A KR102636200B1 (en) | 2020-12-18 | 2020-12-18 | Composition for cultivating cordyceps sinensis containing barley and cheonma as active ingredients and method for culturing cordyceps sinensis using the same |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102636200B1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100922311B1 (en) * | 2009-06-10 | 2009-10-21 | 이태봉 | Methods of culturing Inonotus obliquus, Phellinus linteus, Ganoderma lucidum, Sparassis crispa and Vegetable Worms for production of substances containing AHCC |
| KR101613394B1 (en) * | 2015-04-09 | 2016-05-12 | 백우현 | Feed Additives for Livestock |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100530843B1 (en) * | 2002-11-12 | 2005-11-23 | 주식회사 웰스킨 | Anti-inflammatory composition containing paecilomyces extract and cordyceps extracts as effective composition |
| KR20160147148A (en) * | 2015-06-12 | 2016-12-22 | 빛나래곶감이영농조합법인 | Cultivation method of cordyceps militaris seed mushroom |
| KR102123594B1 (en) * | 2018-08-29 | 2020-06-16 | 농업회사법인 주식회사 모이식품 | Cultivation Method of the Fruiting Bodies of Bio-active Cordyceps sp. Using an Extract of Salvia plebeia |
| KR20200076934A (en) * | 2018-12-20 | 2020-06-30 | 이수용 | Method for obtaining mass proliferation of Cordyceps sinensis and mass culture method using it |
-
2020
- 2020-12-18 KR KR1020200178747A patent/KR102636200B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100922311B1 (en) * | 2009-06-10 | 2009-10-21 | 이태봉 | Methods of culturing Inonotus obliquus, Phellinus linteus, Ganoderma lucidum, Sparassis crispa and Vegetable Worms for production of substances containing AHCC |
| KR101613394B1 (en) * | 2015-04-09 | 2016-05-12 | 백우현 | Feed Additives for Livestock |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220088078A (en) | 2022-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2689951C1 (en) | Mushrooms production method | |
| KR100988072B1 (en) | Fermented dendropanax morbifera lev. products and a pharmaceutical composition comprising the same | |
| KR101309257B1 (en) | Culture media for mushroom cultivation comprising herbal slurgies and mushroom having the activity of anticancer and immunological enhancement produced thereby | |
| KR100799116B1 (en) | A pharmaceutical composition comprising cordycepin for the treatment and prevention of obesity | |
| KR101718323B1 (en) | Pharmaceutical composition containing fermented Rhus verniciflua extracts for prevention or treatment of gastritis, gastric ulcer, duodenal ulcer, gastric cancer and gastric mucosal injury | |
| KR20150074518A (en) | Compositon for preventing and treating diabetes and hypertension comprising fermented broth of plant-originated Lactic acid bacteria | |
| KR100887854B1 (en) | Preventives or Remedies for Arthritis | |
| KR101746388B1 (en) | Phamaceutial composition comprising of dichloromethane fraction of Aster yomena for immune enhancing | |
| KR102143244B1 (en) | Composition for preventing, improving or treating arthritis comprising extract of Ganoderma lucidum, extract of Artemisia princeps or mixture thereof | |
| KR102636200B1 (en) | Composition for cultivating cordyceps sinensis containing barley and cheonma as active ingredients and method for culturing cordyceps sinensis using the same | |
| KR101659927B1 (en) | Enhancing method for pharmaceutical effect of herb, preparation method for fermented chitosan for immune stimulating and its use | |
| KR101871115B1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING ELAEAGNUS MULTRIFLORA Thunb. EXTRACT FOR IMMUNE-ENHANCING | |
| KR101773322B1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING ELAEAGNUS MULTRIFLORA Thunb. EXTRACT FOR IMMUNE-ENHANCING | |
| KR100572405B1 (en) | Process for preparing nontoxic Rhus Verniciflua extract, and the use of the extract | |
| JP4109572B2 (en) | Cordyceps mycelium culture method and composition | |
| KR102368892B1 (en) | A composition for anti-inflammatory comprising extracts of single leaf cremastra and sigesbeckia glabrescens makino | |
| KR102501955B1 (en) | A composition for immune enhancement comprising benicasa hispida extract | |
| KR20090101600A (en) | Composition of matter having plant extracts to improve atopic dermatitis | |
| KR101947276B1 (en) | Composition for immune enhanvement comprising sargassum coreanum enzymatic extract | |
| KR102169046B1 (en) | Antiinflammatory composition comprising enzyme treated larva of Protaetia brevitarsis seulensis | |
| KR101894874B1 (en) | Anti-inflammation Composition Using Streptomyces fragili | |
| KR101890485B1 (en) | Antioxidant Composition Using an Fermentation of Bamboo Shoot | |
| KR102549357B1 (en) | Anti-inflammatory composition containing wheat germ extract | |
| JP5063040B2 (en) | Angiogenesis inhibitor | |
| JPWO2008084574A1 (en) | Angiogenesis inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |